We’re glad to see you’re enjoying ReachMD…but how about a more personalized experience?
Optimizing the Treatment Continuum With a Molecular-Based Approach in HER2+ GI Cancers
June 28, 2024
13:15 - 14:15 CEST
Josep Tabernero, MD, PhD
Sara Lonardi, MD
Zev A. Wainberg, MD
Consolidative Immunotherapy Following sCRT vs RT Only in Stage III NSCLC
Jhanelle E. Gray, MD
Optimizing Consolidative Immunotherapy in Unresectable Stage III NSCLC: Case Discussion
Joshua E. Reuss, MD
Accurate Staging and Determining Resectability in NSCLC
Differentiating and Managing Pneumonitis in Unresectable Stage III NSCLC: Case Discussion
Advances in Immunotherapy for Unresectable Stage III NSCLC
Chemoradiotherapy Toxicities: How Do They Impact Starting Immunotherapy?
Consolidative Immunotherapy in Unresectable Stage III NSCLC With Oncogenic Drivers
Immunotherapy Approaches in Unresectable Stage III NSCLC: What’s on the Horizon?
Resolving Practice Barriers to Consolidative Immunotherapy in Stage III NSCLC
Consolidation Immunotherapy After Concurrent CRT: What Do Real-World Data Show?
Selection of BTK Inhibitor Following Frontline Chemoimmunotherapy in Older Patients With Comorbidities
Mazyar Shadman, MD, MPH
Case by Case: Personalized BTK-Based Approach for Managing CLL/SLL
Safety and Tolerability of Changing Covalent BTK Inhibitor Treatment in a Patient Intolerant to Ibrutinib or Acalabrutinib
Initial BTK Inhibitor-Based Treatment Selection in a Treatment-Naive, Symptomatic, Unfit Older Patient With Comorbidities and High-Risk Cytogenetics
Press cancel to remain on ReachMD. Press the link below or the continue button to keep going.
Stay current with the best on medical education